Streetbeat News

OBIO

Orchestra BioMed Holdings, Inc.

https://orchestrabiomed.com

Industry

Biotechnology

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. has initiated coverage on Orchestra BioMed Holdings with a Buy rating and set a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 11:41 am

Orchestra BioMed Holdings (NASDAQ:OBIO) reported Q2 EPS of $(0.45), missing the $(0.39) estimate, and sales of $778K, beating the $750K estimate. EPS decreased by 28.57% YoY, while sales decreased by 14.97% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:38 pm

B. Riley Securities has initiated coverage on Orchestra BioMed Holdings (NASDAQ:OBIO) with a Buy rating and a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:29 pm

Chardan Capital analyst Keay Nakae has reiterated a Buy rating on Orchestra BioMed Holdings (NASDAQ:OBIO) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:39 am

Orchestra BioMed Holdings (NASDAQ:OBIO) reported Q1 EPS of $(0.38), surpassing the $(0.41) estimate, indicating a 7.32% beat and a 5% improvement from last year's $(0.40) per share. However, their Q1 sales of $620K fell short of the $940K estimate by 34.04%, marking a 46.74% decline from the previous year's $1.16M.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:00 pm

In Thursday's after-market session, health care stocks saw significant movements. Twist Bioscience, Jaguar Health, Tandem Diabetes Care, Indaptus Therapeutics, Ardelyx, and NKGen Biotech were among the gainers, with notable increases in their stock prices following earnings reports. Conversely, Cue Biopharma, Cardiff Oncology, Orchestra BioMed Holdings, Aptevo Therapeutics, Allarity Therapeutics, and Varex Imaging experienced declines.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 8:31 pm

Chardan Capital analyst Keay Nakae has maintained a Buy rating on Orchestra BioMed Holdings (NASDAQ:OBIO) with a $20 price target, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:49 pm

Orchestra BioMed Holdings (OBIO) reported Q4 earnings with a loss of $(0.37) per share, slightly better than the expected $(0.38). However, their sales of $262K fell significantly short of the $990K estimate, marking a substantial year-over-year decline in performance.

Portfolio Pulse from Happy Mohamed

March 28, 2024 | 3:46 am

Jefferies analyst Matthew Taylor has initiated coverage on Orchestra BioMed Holdings (NASDAQ:OBIO) with a Buy rating and set a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 11:28 am

Orchestra BioMed Holdings (NASDAQ: OBIO) reported a narrower Q3 loss of $(0.38) per share compared to $(0.51) YoY, but sales declined to $419.00K from $1.16M YoY, indicating a mixed financial performance.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.